Craneware Share Price (CRW)

War

...from last year...

Today’s company provides healthcare institutions with something crucial for the long-term prosperity of such entities – optimization of financial and operational performance. The firm argues that roughly $22 million in revenue are not captured from the average 350-bed hospital, and that is a lot even in the world of hyper expensive testing and analysis robots a modern hospital has. Craneware’s ambition is to reduce the foregone profits through its cycle experts and innovative technology which ensure transparency. They have 11  key products in their portfolio, which tackle different parts of the revenue generation cycle of each hospital. The company was founded in 1999 and currently has offices in UK and USA ad serves more than 1/3rd of the registered hospitals on US soil.
The company is growing organically, without any big acquisitions during the past 10 years. Goodwill for the period ending June 2021 was at $11.1m, or 3% which is negligible. Growth in the fundamentals is strong, with revenue CAGR of 8.68% and EPS at 4.06%. Return on capital employed is growing at 25.5% on compound basis and net gearing is negative. Return on equity is in the top quartile of the industry at 7.9% and dividends are growing at 11.6% CAGR.
Today they have released their final results for the FY 2021 (ending in June). Revenue swelled by 6% reaching $75.6m. PBT is below last year’s figures at $13.2m due to exceptional costs from the acquisition they did. As a result, EPS is down on 2020 figures to 48.1 cents. They have increased their expenditures on R&D and proposed an increase in dividends from 18.45 cents to 21.47 cents. Outlook is positive and momentum in sales is sustained in the new financial period. Management is “ confident in return to double digit organic growth”.

Projects: During the period the company acquired Sentry – a leading provider of SaaS solutions that simplify the complexity of pharmacy procurement, utilisation and regulatory compliance.

Short analysis:

Cash increased significantly over the period due to share issuance, causing a dilution
Net cash position
CA/CL = 5.16
Cash ratio = 4.77
Interest coverage = 140
P/S = 15.36, which is very high even for the sector
BV ps = 788c, growing at 32% CAGR
Operating profit $13.2m
Gross profit margin 93%...

...from WealthOracleAM

https://wealthoracle.co.uk/detailed-result-full/CRW%20/186

Hard to find such strong results

I to am searching for an explanation. Shares seem to being dumped in vast numbers,but why ?

Why is this dropping so much when there's no bad news?